Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-05-10
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess whether Roxadustat can reduce perioperative blood transfusions in patients with anemia undergoing elective lumbar interbody fusion surgery. It will also evaluate the safety of Roxadustat in this context. The main questions it aims to answer are:
* Does Roxadustat reduce the need for perioperative red blood cell transfusions?
* Is Roxadustat safe for use in patients during the perioperative period?
Researchers will compare Roxadustat to standard clinical care without Roxadustat to determine its effectiveness and safety.
Participants will:
* Take Roxadustat orally three times a week for three weeks (two weeks before surgery and one week post-surgery).
* Undergo regular blood tests and follow-up monitoring during the hospital stay and up to 6 months after surgery.
Phase:
PHASE3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University